Project description
Fellowship to study prescription drugs during pregnancy
What are the risks and benefits of prescribed drug use during pregnancy? This question will be investigated by the newly established ‘International Pregnancy Safety Study’ (InPreSS) consortium, which brings together research groups with access to healthcare databases and demonstrated ability to study the safety of medications in pregnancy. This EU-funded project offers a global fellowship position at InPreSS. The fellow will be based at the Centre for Pharmacoepidemiology, Karolinska Institute (CPE/KI) in Sweden, with collaborators including researchers in all five Nordic countries and the Harvard School of Public Health (HSPH) in the US. The fellow will receive the highest quality support, facilitating long-term partnerships, training and contributing to the field with studies that impact clinical practice and guidelines for pregnant women.
Objective
This is a proposal for a global fellowship position within the International Pregnancy Safety Study (InPreSS), a recently established international collaboration based at the Centre for Pharmacoepidemiology, Karolinska Institute (CPE/KI), Sweden, between researchers in all five Nordic countries and the Harvard School of Public Health (HSPH), USA. The majority of pregnant women take prescription drugs but there is limited evidence of their efficacy and safety. InPreSS aims to conduct exceedingly important research into the risk and benefits of prescribed drug use during pregnancy. The overarching objective of this fellowship is to provide advanced training in reproductive pharmacoepidemiology while creating a platform from which to launch an independent academic career in the EU. Three specific aims are to: 1) investigate the efficacy/safety of prescribed drugs used treatment of diabetes during pregnancy; 2) to trial the InPreSS international research model to evaluate short- and long-term infant and maternal health outcomes following use of prescribed drugs for chronic disease treatment during pregnancy using an unparalleled global resources of over 5 million pregnancies; 3) provide experience and mentorship at HSPH to design and deliver courses in pharmacoepidemiology in Sweden. Aims will be achieved via an 18-month out-going phase at HSPH where the Fellow will use the latest methodologies in pharmacoepidemiology to analyze a dataset comprised of US health insurance data, and a 12-month return-phase at CPE/KI where the results will be combined using meta-regression techniques. The Fellow will receive the highest quality support while facilitating long-term partnerships, training the next generation of researchers, and contributing to the field with studies that will directly impact clinical practice and guidelines for pregnant women.
Fields of science
Keywords
Programme(s)
Funding Scheme
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinator
17177 Stockholm
Sweden